Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Myelodysplastic syndromes
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 365 for your search:
Start Over
Efficacy of G-CSF-Priming in Elderly AML Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
Phase: Phase IV
Type: Treatment
Status: Active
Age: 10 to 90
Sponsor: Other
Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985
A Phase ? Study of Decitabine in Myelodysplastic Syndrome
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DREAM-201, NCT02013102
An Open-Label Study of Recormon (Epoetin Beta) Treatment in Anemic Patients With Myelodysplastic Syndromes
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML29005, NCT02145026
Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 0 to 18
Sponsor: Other
Protocol IDs: CHU-0060, NCT01007617
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
A Study of LY2157299 in Participants With Myelodysplastic Syndromes
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15242, H9H-MC-JBAV, 2013-003235-30, NCT02008318
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879
Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: RICMAC, EBMT 42205525, NCT00682396
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: MC-FludT.14/L, EudraCT-No.: 2008-002356-18, NCT00822393
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01173, CDR0000634119, ECOG-E2905, E2905, U10CA180820, U10CA021115, NCT00843882
Randomized Allogeneic Azacitidine Study
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-0503, NCI-2012-01259, NCT00887068
Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: MDS201001, 2009-017462-23, CRUK/08/009, NCT01196715
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20120673, NCT01237639
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SINTRA-REV, 2009-013619-36, NCT01243476
Comparison of Cy-Atg Versus Flu-Atg for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Bone Marrow Failure Syndrome
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: C-021, NCT01145976
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: 2081-076, NCT01530581
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467
Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0737, NCI-2013-00704, NCT01787487
Start Over